MoonLake Immunotherapeutics analysts slash target price as trial results disappointProactive Investors • 09/29/25
BREAKING: MoonLake Immunotherapeutics Shares Down Over 85%; Investors Should Contact Block & Leviton to Potentially Recover LossesGlobeNewsWire • 09/29/25
Inventiva, MoonLake Immunotherapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market SessionBenzinga • 09/29/25
MoonLake Immunotherapeutics reports on week 16 results of the VELA Phase 3 hidradenitis suppurativa program with the Nanobody® sonelokimabGlobeNewsWire • 09/28/25
MoonLake Immunotherapeutics Reports Second Quarter 2025 Financial Results and Provides a Business UpdateGlobeNewsWire • 08/05/25
MoonLake Immunotherapeutics: More Sonelokimab Success, With Big Pharma InterestSeeking Alpha • 06/03/25
Wall Street Analysts Think MOONLAKE IMMUNO (MLTX) Could Surge 106.62%: Read This Before Placing a BetZacks Investment Research • 05/15/25
MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business UpdateGlobeNewsWire • 05/12/25
MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29GlobeNewsWire • 04/25/25
MoonLake Secures up to $500 Million in Non-Dilutive Financing from Hercules Capital and Announces a Capital Markets Update on April 29 to Provide Important Clinical UpdatesGlobeNewsWire • 04/03/25
MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business UpdateGlobeNewsWire • 02/26/25
MoonLake Immunotherapeutics: Mid-2025 Sonelokimab HS Data Could Be Enhanced UponSeeking Alpha • 01/17/25
MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimabGlobeNewsWire • 01/08/25
MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11GlobeNewsWire • 09/09/24